期刊文献+

应对和化解由抗血小板药抵抗所带来的困惑 被引量:1

下载PDF
导出
摘要 抗血小板药在心脑血管不良事件的预防中成效卓著,其业绩和地位已被多项循证医学研究结果所确立。国际上已在6个RCT(BMD、HOT、PPP、PHS、TPT和WHS)总计98 000例心脑血管疾病高危因素者中进行评价,结果阿司匹林能使血管事件的总发生率下降15%,心肌梗死和冠心病死亡的危险性总体降低23%。英国医学杂志通过读者评选将阿司匹林列为全球医药学十大重大突破性成就之一。但伴随抗血小板药在临床应用上日趋广泛,对血小板药抵抗的问题也随之而来,为临床带来新的困惑,产生抵抗的因素繁多,包括基因、环境、用药等诸多方面,临床必须面对,以突破瓶颈、化解矛盾,延续百年老药的辉煌。
作者 张石革
出处 《中国医院用药评价与分析》 2012年第9期769-772,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
  • 相关文献

参考文献21

  • 1Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondmy prevention of vascular disease:collaborative meta-analysis of individual participant data from randomized trials [ J ]. Lancet,2009,373 (9678) : 1849-1860.
  • 2Becker RC. Aspirin and the prevention of venous thrombo- embolism[ J ]. N Engl J Med, 2012, 366 ( 21 ) : 2028- 2030.
  • 3孙宁玲.阿司匹林与心脑血管疾病一级预防:2011新进展[J].中国实用内科杂志,2012,32(1):79-80. 被引量:30
  • 4Orford JL, FasseasP, Melby S ,et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation [ J ]. A m Heart J, 2004,147 ( 3 ) : 463-467.
  • 5李伟玲,刘品发,佘海茹.氯吡格雷抵抗的治疗及进展[J].青海医药杂志,2010,40(12):77-79. 被引量:5
  • 6AleilB, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [ J ]. J Thromb Haemost ,2005,3 ( 1 ) : 85 -92.
  • 7Ziegler S, SehillingerM, Funk M, et al. Association of a functional polymorphism in the clopidogrel target receptor gene P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease [ J ]. Stroke ,2005,36(7 ) : 1394-1399.
  • 8Sibbing D, Koch W, Gebhard D ,et al. Cytochrome 2C19 * 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement [ J ]. Circulation, 2010, 121 ( 4 ) : 512-518.
  • 9Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose [J]. Thromb Haemost, 2004,92(2) :311-316.
  • 10韩雅玲,王守力,李毅,荆全民,马颖艳,王祖禄,王冬梅,栾波,王效增.急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J].中国介入心脏病学杂志,2005,13(1):9-12. 被引量:53

二级参考文献46

  • 1韩雅玲,王守力,李毅,荆全民,马颖艳,王祖禄,王冬梅,栾波,王效增.急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J].中国介入心脏病学杂志,2005,13(1):9-12. 被引量:53
  • 2Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction : a cohort study [ J ]. Lancet, 2009,373 (9 660) :309.
  • 3Mega JL, Close SL, Wiviott SD, et al. Cytochrome P- 450 polymorphisms and response to clopidogrel [ J ]. N Engl J Med,2009,360(4):354.
  • 4Simon T, Verstuyft C, Mary- Krause M, et al. Geneti determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med ,2009,360(4) :363.
  • 5Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss- of- function polymorphism and stent thrombosis following percutaneous coronary intervention[J]. Eur Heart J, 2009,30(8) :916.
  • 6Angiolillo D J, Fernandez - Ortiz A, Bemardo E, et al. PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation [ J] . Blood Coagul Fibrinol~'sis, 2004,15 ( 1 ) : 89.
  • 7Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence[J].J Am Coll Cardiol, 2005,45(8) :1 157.
  • 8Chen L, Qin S, Xie J, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of China's Mainland [ J ] . Pharmacogenomics, 2008,9(6) :691.
  • 9Garcia- Barcelo M, Chow LY, Kum Chiu HF, et al. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population [ J ]. Clinical Chemistry, 1999,45 ( 12 ) : 2 273.
  • 10Roden DM, Stein CM. Clopidogrel and the Concept of High - Risk Pharmacokinetics [ J ]. Circulation, 2009, 119 ( 16 ) : 2 127.

共引文献96

同被引文献14

  • 1Guidetti G F,Canobbio I,Torti M.PI3K/Akt in platelet integrin signaling and implications in thrombosis.Advances in Biological Regulation,2015;(59)∶36-52.
  • 2Longa E Z,Weinstein P R,Carlson S,et al.Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke,1989;20(1)∶84-91.
  • 3Semenov A V,Kogan-Ponomarev M,Ruda M,et al.Soluble P-selectin-a marker of platelet activation and vessel wall injury∶increase of soluble P-selectin in plasma of patients with myocardial infarction,massive atherosclerosis and primary pulmonary hypertension..Ter Arkh,2000;72(4)∶15-20.
  • 4Petersen H J,Keane C,Jenkinson H F,et al.Human platelets recognize a novel surface protein,Pad A,on Streptococcus gordonii through a unique interaction involving fibrinogen receptor GPIIb IIIa.Infect Immun,2010;78(1)∶413-422.
  • 5Wang Q,Zhao W,Bai S.Association between plasma soluble P-selectin elements and progressive ischemic stroke.Exp Ther Med,2013;5(5)∶1427-1433.
  • 6J ackson S P,Schoenwaelder S M,Goncalves I,et al.PI 3-kinase p110beta∶a new target for antithrombotic therapy.Nat Med,2005;11(5)∶507 -514.
  • 7Dangelmaier C,Manne B K,Liverani E,et al.PDK1 selectively phosphorylates Thr(308)on Akt and contributes to human platelet functional responses.Thromb Haemost,2014;111(3)∶508-517.
  • 8Zhao S,Guan K L,Substrate selectivity APPLies to Akt.Cell,2008;133(3)∶399-400.
  • 9Chen X,Zhang Y,Wang Y,et al.PDK1 regulates platelet activation and arterial thrombosis.Blood,2013;121(18)∶3718-3726.
  • 10张宽,杨彩媚,庞文生,韩静,胡娟.补阳还五汤抗血小板聚集作用[J].中国民族民间医药,2013,22(1):42-42. 被引量:5

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部